Table 1.
Distribution of baseline characteristics of 290 metastatic NSCLC patients according to AAPR level
| Characteristics | Total, n (%) | AAPR ≤0.36, n (%) | AAPR >0.36, n (%) | P-value |
|---|---|---|---|---|
| Number of patients | 290 | 89 (30.7） | 201 (69.3） | |
| Age (years) | 0.898 | |||
| ≤60 | 162 (55.9) | 49 (55.1) | 113 (56.2) | |
| >60 | 128 (44.1) | 40 (44.9) | 88 (43.8) | |
| Gender | 0.696 | |||
| Male | 176 (60.7) | 56 (62.9) | 120 (59.7) | |
| Female | 114 (39.3) | 33 (37.1) | 81 (40.3) | |
| Smoking status | 1.000 | |||
| Current/past | 139 (47.9) | 43 (48.3) | 96 (47.8) | |
| Never | 151 (52.1) | 46 (51.7) | 105 (52.2) | |
| Histology | 0.502 | |||
| SCC | 60 (20.7) | 15 (16.9) | 45 (22.4) | |
| ADC | 215 (74.1) | 70 (78.7) | 145 (72.1) | |
| Others | 15 (5.2) | 4 (4.5) | 11 (5.5) | |
| Number of metastasis sites | 0.001* | |||
| ≤2 | 242 (83.4) | 64 (71.9) | 178 (88.6) | |
| >2 | 48 (16.6) | 25 (28.1) | 23 (11.4) | |
| Liver/bone metastasis | 0.011* | |||
| Positive | 140 (48.3) | 53 (37.9) | 87 (62.1) | |
| Negative | 150 (51.7) | 36 (24.0) | 114 (76) | |
| Systemic therapy | 0.007* | |||
| Yes | 196 (67.6) | 50 (56.2) | 146 (72.6) | |
| No | 94 (32.4) | 39 (43.8) | 55 (27.4) | |
| Albumin (g/L), median (range) | 37.97 (23.5–64.8) | 35.32 (23.5–45.9) | 39.14 (28.2–64.8) | 0.000* |
| ALP (U/L), median (range) | 121.73 (1.46–2,170.0) | 221.80 (79.0–2,170.0) | 77.43 (1.46–119.0) | 0.000* |
| LDH (U/L) | 0.001* | |||
| ≤265.5 | 234 (80.7) | 61 (68.5) | 173 (86.1) | |
| >265.5 | 56 (19.3) | 28 (31.5) | 28 (13.9) |
Note: *P<0.05.
Abbreviations: AAPR, albumin-to-alkaline phosphatase ratio; ADC, adenocarcinoma; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.